Trial Profile
A Phase I/II Trial of NAITgam (anti-HPA-1a Immunoglobulin) for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 22 Jun 2015
Price :
$35
*
At a glance
- Drugs RLYB 211 (Primary)
- Indications Thrombocytopenia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Prophylix Pharma
- 22 Jun 2015 New trial record